Cargando…

ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding − A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.

Detalles Bibliográficos
Autor principal:	Sergi, Consolato M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921953/ https://www.ncbi.nlm.nih.gov/pubmed/35350678 http://dx.doi.org/10.1159/000521812

Ejemplares similares

Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication
por: Shehi, Elona, et al.
Publicado: (2021)

Apixaban: Gastrointestinal bleeding: case report
Publicado: (2021)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
por: Attelind, Sofia, et al.
Publicado: (2022)

Apixaban/enoxaparin-sodium/parnaparin-sodium: Muscle bleeding, haemoptysis and gastrointestinal bleeding: 5 case reports
Publicado: (2021)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation
por: Mukai, Yutaro, et al.
Publicado: (2017)

Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
por: Yen, Hung-Wen
Publicado: (2019)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
por: Kim, Hamin, et al.
Publicado: (2023)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
por: Limcharoen, Sutee, et al.
Publicado: (2022)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series
por: Piccoli, Giorgina B, et al.
Publicado: (2011)

Apixaban and oral implications
por: Lopez-Galindo, Monica, et al.
Publicado: (2015)

Apixaban-Induced Hepatotoxicity
por: Ansari, Umair, et al.
Publicado: (2022)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications
por: Sin, Chun-fung, et al.
Publicado: (2022)

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage
por: Herzog, E., et al.
Publicado: (2015)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Implications of apixaban for dental treatments
por: Curto, Adrian, et al.
Publicado: (2016)

Quick reference guide to apixaban
por: Hurst, Katherine Victoria, et al.
Publicado: (2017)

Apixaban: Haematochezia: case report
Publicado: (2021)

Apixaban-Induced Skin Purpura
por: Rodríguez, Miryam Moreta, et al.
Publicado: (2021)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
por: Leil, T A, et al.
Publicado: (2014)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights
por: Gulilat, Markus, et al.
Publicado: (2021)

Apixaban as a Rare Cause of Leukocytoclastic Vasculitis
por: Spears, Jenna, et al.
Publicado: (2020)

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
por: Huppertz, Andrea, et al.
Publicado: (2019)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model
por: Herzog, E, et al.
Publicado: (2015)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Quick reference guide to apixaban [Corrigendum]
Publicado: (2017)

The use of Apixaban for the treatment of an LV thrombus
por: Bennett, Sadie, et al.
Publicado: (2018)

Atraumatic splenic rupture associated with apixaban
por: Basnet, Sijan, et al.
Publicado: (2019)

Case report: apixaban‐induced thrombocytopenia
por: Snellgrove, Oliver
Publicado: (2017)

Rectus Sheath Hematoma Associated with Apixaban
por: Gunasekaran, Kulothungan, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_73ch2stl6q6d9b1tc09btn8fdb